A rapid, low-cost test kit that detects soluble acrylamide by measuring its effect on bacterial metabolism and growth rates. Using disk diffusion with a reference E. coli strain, the method achieves parts-per-billion sensitivity in under 8 hours at under $5 per sample, with a 3-hour option available with added instrumentation. Designed for food and beverage industry quality control.
This solution offers a rapid, affordable method for detecting soluble acrylamide in liquid samples by leveraging the natural inhibitory effect of acrylamide on bacterial metabolism. The approach adapts proprietary bacterial growth-rate characterization technology—originally developed for clinical diagnostics—to food and beverage safety testing. By combining paper disks loaded with test samples and select antibiotics in a standard disk diffusion assay, users can visually or instrument-read an inhibition zone whose size correlates with acrylamide concentration. The result is a sensitive, field-deployable detection method that delivers actionable results in hours rather than the days required by conventional laboratory techniques.
How it works:
Key features and performance:
Practical applications:
The concept is supported by preliminary experimental data demonstrating ppb-level detection of acrylamide within an 8-hour assay. Next steps include aligning the test format and turnaround time with end-user requirements (for example, determining whether 8-hour or 3-hour results are needed), refining the assay design, and generating formal validation data. Initial end-user training materials will be developed alongside the optimized kit. The underlying bacterial metabolism measurement technology is already being commercialized for clinical use, providing a strong foundation for translating the approach into a food-safety testing product.
Spectral Platforms is a biotechnology company focused on developing rapid diagnostic solutions for clinical microbiology. The company has created proprietary technology that detects bacterial pathogens by measuring metabolic markers and redox state changes in clinical samples. This approach aims to bypass traditional, time-consuming culture methods, offering diagnostic results for bacteria presence within 30 minutes. By enabling faster identification and antimicrobial susceptibility testing (AST), the platform is designed to provide actionable data for clinicians to initiate effective antibiotic therapy significantly earlier than current standards allow.
This technology is primarily intended for use in triaging patients at risk of sepsis and managing infectious diseases. By providing rapid and reliable results, including AST results for both single and poly-microbial samples, the company seeks to improve patient outcomes and optimize clinical decision-making. Founded in 2010 and based in Duarte, California, Spectral Platforms engages in research and development for the medical diagnostics industry, often working within the healthcare, biotechnology, and life sciences sectors to validate its diagnostic innovations for clinical environments.